PharmaShots
FEBRUARY 1, 2023
Ximluci is expected to be available in the UK in 2023 The approval for Ximluci was granted through the EC decision reliance procedure, whereby the MHRA’s decision was based on the EC Ximluci was approved in the UK for wet AMD, DME, diabetic retinopathy, RVO, and visual impairment due to choroidal neovascularization in adults.
Pharmaceutical Technology
JULY 15, 2022
In a budget change proposed in February and confirmed in May , California’s Department of Health Care Access and Information (HCAI) requested a one-time investment of $100 million for Newsom’s CalRx Biosimilar Insulin initiative. The state plans to work directly with a contract manufacturing organization (CMO) to manufacture low-cost insulin.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaShots
JUNE 7, 2023
Our team at PharmaShots has summarized 16 key events of the biosimilar space of May 2023 1. Sandoz Reports Real World Study Results of GP2013 (biosimilar, rituximab) for the Treatment of Rheumatoid Arthritis Date- May 08, 2023 Product: GP2013 (biosimilar, rituximab) The study incl. 84% vs 64%) & 2yr. (60%
European Pharmaceutical Review
FEBRUARY 22, 2023
1 Used to treat a range of chronic diseases (eg, diabetes, rheumatoid arthritis, psoriasis, Crohn’s disease, haemophilia, etc), it is projected that the sales of biologics will rise from $380 billion in 2022 to $416 billion in 2023, and to almost $600 billion in 2027. Diabetes Therapy. the enteric coating and the capsule dissolve.
PharmaShots
FEBRUARY 27, 2023
Manan Sharma- “as from the technology side I will start with the recently used cases like the government of India has already made it mandatory for around 300 drugs to have their barcode on the packaging to track and trace the information of the drugs. We can order drugs online and can have online consultations. Dr. Mangesh.
Expert insights. Personalized for you.
40 
Let's personalize your content